Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Surg. 1995 Mar;130(3):257-61.

Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia.

Author information

  • 1Department of Surgery, Washington University School of Medicine, St. Louis, Mo.

Erratum in

  • Arch Surg 1995 Jun;130(6):616.

Abstract

OBJECTIVE:

To determine if halofuginone hydrobromide, a specific type I collagen inhibitor, could prevent intimal hyperplasia at a vascular anastomosis.

DESIGN:

Intimal hyperplasia is characterized by smooth muscle cell proliferation and extracellular matrix accumulation. Halofuginone was used to block collagen production and smooth muscle cell proliferation in cell cultures and in a rabbit model of an end-to-end anastomosis of the right common carotid artery. Animals were fed a nontoxic dose of halofuginone. Eighteen rabbits were fed the inhibitor in a randomized blinded fashion and were examined after 4 weeks by harvesting the arteries after perfusion fixation at physiologic pressures.

RESULTS:

Halofuginone inhibited smooth muscle cell proliferation in vitro and had no effect on cell viability. Morphometric quantification verified that halofuginone treatment significantly attenuated anastomotic intimal thickness.

CONCLUSION:

Oral administration of halofuginone inhibits intimal hyperplasia at vascular anastomoses. Intimal hyperplasia inhibition by halofuginone may be a therapeutic option for preventing arterial stenosis in vascular surgery.

PMID:
7887792
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk